 Alnylam Pharmaceuticals Incs ALNY Q4 product revenues increased 76 YY to 198.5 million, primarily due to the continued global expansion of Onpattro and Givlaari, and sales from a third commercial product, Oxlumo. Get the Inside Access Traders Are Using to Profit More and Win Bigger. 